Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trialKanwal Raghav, Takayuki Yoshino, Marc Van den Eynde et al.|The Lancet Oncology|2024Cited by 124
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.Kanwal Raghav, Takayuki Yoshino, Salvatore Siena et al.|Journal of Clinical Oncology|2023Cited by 77